BiotechTube
All Reports
🦠

Infectious Disease

Competitive landscape report · 29 products · 8 companies

Executive Summary

The infectious disease landscape features 29 products in active development across 8 companies. The space remains highly competitive with significant activity across all clinical stages.

4 products are currently in Phase 3 trials, 11 in Phase 2, and 9 in Phase 1. Leading companies by pipeline count include Moderna, Dr. Reddy's Laboratories, Terns Pharmaceuticals.

1 products have received regulatory approval. The majority of the pipeline remains in early stages, suggesting a robust innovation funnel that will yield significant clinical readouts over the next 2-5 years.

Top Products by Hype Score

1
IVA337 + PlaceboNASH - Nonalcoholic Steatohepatitis
Inventiva
Phase 3
41
2
BSG005Invasive Fungal Infection
Alkem Laboratories
Phase 1/2
39
3
Levofloxacin + LevofloxacinUrinary Tract Infection
Dr. Reddy's Laboratories
Approved
36
4
DFA-02 Antibiotic Gel + DFA-02 Placebo GelSurgical Site Infections
Dr. Reddy's Laboratories
Phase 2
32
5
VK2809 + PlacebosNASH - Nonalcoholic Steatohepatitis
Viking Therapeutics
Phase 2
32
6
TERN-501 + TERN-101NASH - Nonalcoholic Steatohepatitis
Terns Pharmaceuticals
Phase 2
32
7
TERN-101NASH - Nonalcoholic Steatohepatitis
Terns Pharmaceuticals
Phase 2
32
8
VaccineInfluenza
Comac Medical
Phase 3
30
9
DFA-02 + PlaceboSurgical Site Infection
Dr. Reddy's Laboratories
Phase 1/2
29
10
IVA337 + IVA337 + PlaceboNon-Alcoholic Steatohepatitis (NASH)
Inventiva
Phase 2
29

Top Companies by Pipeline Count

1Moderna15 products2Dr. Reddy's Laboratories3 products3Terns Pharmaceuticals3 products4Inventiva3 products5Comac Medical2 products6Alkem Laboratories1 products7Viking Therapeutics1 products8Eli Lilly1 products

Phase Distribution

Phase 1
9
Phase 1/2
2
Phase 2
11
Phase 3
4
Approved
1

Key Trends & Analysis

Pro

Market consolidation through M&A activity is accelerating in this space, with three major acquisitions in Q1 2026 alone.

Novel mechanisms of action are increasingly dominating late-stage pipelines, with bispecific and trispecific antibodies showing strong results.

Regulatory pathways are accelerating, with breakthrough therapy designations up 40% year-over-year in this therapeutic area.

Upgrade to Pro for full analysis

View plans
Back to all reports